{"organizations": [], "uuid": "440a54582799949bd8642bc2428429b2efb220f6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/teva-pharm-ind-logistics/teva-pharma-opts-to-maintain-israeli-logistics-centre-idUSL8N1S92CE", "country": "US", "domain_rank": 408, "title": "Teva Pharma opts to maintain Israeli logistics centre", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T12:10:00.000+03:00", "replies_count": 0, "uuid": "440a54582799949bd8642bc2428429b2efb220f6"}, "author": "", "url": "https://www.reuters.com/article/teva-pharm-ind-logistics/teva-pharma-opts-to-maintain-israeli-logistics-centre-idUSL8N1S92CE", "ord_in_thread": 0, "title": "Teva Pharma opts to maintain Israeli logistics centre", "locations": [], "entities": {"persons": [{"name": "tova cohen", "sentiment": "none"}, {"name": "steven scheer", "sentiment": "none"}], "locations": [{"name": "israel", "sentiment": "none"}], "organizations": [{"name": "teva pharma", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "teva pharmaceutical industries", "sentiment": "none"}, {"name": "sle", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 9:10 AM / Updated 12 minutes ago Teva Pharma opts to maintain Israeli logistics centre Reuters Staff 1 Min Read\nJERUSALEM, May 2 (Reuters) -\n* Teva Pharmaceutical Industries said on Wednesday it had decided not to sell its SLE logistics centre in Israel.\n* Last December, as part of a cost cutting programme, Teva said it was considering the sale of SLE.\n* After an examination and taking into account all of the business considerations, Teva decided not to maintain SLE’s activity.\n* “Teva Israel as well as Teva and its manufacturing sites will continue to enjoy SLE’s services. SLE will continue to be one of the main storage solutions for Teva and the main distribution arm for the products and services Teva promotes in Israel, along with the other third party pharmaceutical companies whose products SLE distributes,” it said.\n* Teva stressed the decision was made “despite the great interest of dozens of potential buyers”. (Reporting by Steven Scheer; Editing by Tova Cohen)", "external_links": [], "published": "2018-05-02T12:10:00.000+03:00", "crawled": "2018-05-02T12:23:52.008+03:00", "highlightTitle": ""}